DSM-Firmenich and Californian biotech outfit Inscripta have formed a strategic partnership focused on developing what the former claims is a novel and highly sought after well-ageing skin care ingredient.
The partnership will see Inscripta will bring its expertise in microbial strain engineering using its proprietary GenoScaler platform—a next-generation technology which leverages proprietary whole genome engineering to deliver robust industrial scale bio-manufacturing.
“Partnering with DSM-Firmenich allows us to demonstrate the full potential of biotechnology in the beauty industry,” said Sri Kosaraju, President and CEO at Inscripta.
“Our GenoScaler platform, combined with DSM-Firmenich’s vast experience in biotech, presents new opportunities for creating bio-active ingredients that meet the high-performance standards of today’s skin care market, while also addressing the growing demand for sustainability.”
The collaboration between DSM-Firmenich and Inscripta combines scientific innovation and environmental responsibility to drive rapid, cost-effective solutions for customers.
This partnership ensures supply chain security, scalability, consistent quality, and efficient use of natural resources.
“As leaders in biotechnology, at dsm-firmenich we are thrilled to collaborate with Inscripta, a well-respected innovator in biotech strain engineering,” said Parand Salmassinia, President of Beauty & Care at DSM-Firmenich.
“By integrating Inscripta’s scientific knowledge with our biotechnology skincare expertise, we’re set to deliver next-generation well-aging products that offer superior results while contributing to a more sustainable future,” she added.
“Our biotech leadership will ensure that we not only meet consumer expectations but exceed them”.
